XPO1 and plasma cell myeloma: It has been shown that at increased cell densities and in myeloma cells, Topo IIα is exported to the cytoplasm in a CRM1-dependent fashion rendering the cells resistant to Topo IIα-specific inhibitors, which rather act on the DNA-bound nuclear protein [99,115,116].